Analysis of sexual function of patients with polycystic ovary syndrome with different clinical phenotypes

doi:10.3969/j.issn.1006-7795.2024.04.009

Abstract

Abstract: Objective To investigate the sexual function of different clinical phenotypes in patients with polycystic ovarian syndrome (PCOS) and its correlation with clinical and sex hormonal characteristics. Methods The study evaluated sexual function on PCOS patients and control women in the Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University from October 2020 to December 2021, via the Chinese version of Female Sexual Function Index (FSFI). PCOS were divided into four clinical phenotype groups according to the Rotterdam criteria, A: oligo-ovulation or anovulation (OA) + hyperandrogenism (HA) + polycystic ovaries (PCO); B: OA + HA; C: HA+ PCO; D: OA +PCO. The clinical data that may affect sexual function were collected and sex hormone levels were measured, including anthropometric markers, serum follicle-stimulating hormone, luteinizing hormone, prolactin and total testosterone. Results A total of 910 PCOS women and 402 control women with complete parameters were included in the study. Phenotype A had the lowest total FSFI mean score (23.69±3.20) (P <0.05); phenotype B, C and D showed a trend of sequential increase. Control group had the highest total FSFI mean score (24.96±3.79) (P <0.05). Compared with the control group, Group A had the highest risk percentage of female sexual dysfunction (FSD) at 87.5% (P <0.05), followed by Group B, Group C, and Group D. The control group had the lowest FSD risk percentage, which was 62.19% (P <0.05). The FSD risk in Group A was higher than that in Group C and Group D (P <0.05), while the FSD risk in Group B was higher than that in Group D (P <0.05). Multivariate linear regression analysis demonstrated that total testosterone (TT), age, waist circumference, and body fat distribution were negatively correlated with female sexual function. Conclusions Compared with the control group, PCOS patients have a higher risk of FSD and are associated with the clinical phenotype of PCOS. The classic phenotype that simultaneously meets the three diagnostic characteristics of PCOS has the highest risk of FSD. TT, age, waist circumference, and body fat distribution are associated with FSD risk in PCOS women.

Key words: olycystic ovary syndrome, sexual function, clinical phenotypes, correlation

CLC Number:

R711.7

Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Ju Rui, Du Juan, Cheng Jiaojiao, Yang Yu. Analysis of sexual function of patients with polycystic ovary syndrome with different clinical phenotypes[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2024.04.009.

References

［1］ Tian X X, Ruan X Y, Du J, et al. Sexual function in Chinese women with polycystic ovary syndrome and correlation with clinical and biochemical characteristics［J］. Reprod Sci, 2021, 28(11): 3181-3192.
［2］ Du J, Ruan X Y, Gu M Q, et al. Prevalence of and risk factors for sexual dysfunction in young Chinese women according to the female sexual function index: an internet-based survey［J］. Eur J Contracept Reprod Health Care, 2016, 21(3): 259-263.
［3］ Lou W J, Chen B, Zhu L, et al. Prevalence and factors associated with female sexual dysfunction in Beijing, China［J］. Chin Med J, 2017, 130(12): 1389-1394.
［4］ Loh H H, Yee A N, Loh H S, et al. Sexual dysfunction in polycystic ovary syndrome: a systematic review and Meta-analysis［J］. Hormones, 2020, 19(3): 413-423.
［5］ Eftekhar T, Sohrabvand F, Zabandan N D, et al. Sexual dysfunction in patients with polycystic ovary syndrome and its affected domains［J］. Iran J Reprod Med, 2014, 12(8): 539-546.
［6］ Dashti S, Latiff L A, Hamid H A, et al. Sexual dysfunction in patients with polycystic ovary syndrome in Malaysia［J］. Asian Pac J Cancer Prev, 2016, 17(8): 3451-3747.
［7］殷冬梅, 阮祥燕, 赵越, 等. 北京地区多囊卵巢综合征病人内分泌代谢特征分析［J］. 首都医科大学学报, 2017, 38(4): 498-503.
［8］ Rocha A L, Oliveira F R, Azevedo R C, et al. Recent advances in the understanding and management of polycystic ovary syndrome［J］. F1000Res, 2019, 8: 565.
［9］ Shindel A W, Ferguson G G, Nelson C J, et al. The sexual lives of medical students: a single institution survey［J］. J Sex Med, 2008, 5(4): 796-803.
［10］ Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and Meta-analysis［J］. Hum Reprod, 2016, 31(12): 2841-2855.
［11］ Tavares A, Rêgo B R C. The prevalence of metabolic syndrome in the different phenotypes of polycystic ovarian syndrome［J］. Rev Bras Ginecol Obstet, 2019, 41(1): 37-43.
［12］ Imprialos K P, Koutsampasopoulos K, Katsimardou A, et al. Female sexual dysfunction: a problem hidden in the shadows［J］. Curr Pharm Des, 2021, 27(36): 3762-3774.
［13］ Zsoldos M, Pajor A, Pusztafalvi H. Relation between sexual dysfunction and metabolic syndrome［J］. Orv Hetil, 2019, 160(3): 98-103.
［14］ Daneshfar Z, Jahanian Sadatmahalleh S, Jahangiri N. Comparison of sexual function in infertile women with polycystic ovary syndrome and endometriosis: a cross-sectional study［J］. Int J Reprod Biomed, 2022, 20(9): 761-768.
［15］ Basirat Z, Faramarzi M, Esmaelzadeh S, et al. Stress, depression, sexual function, and alexithymia in infertile females with and without polycystic ovary syndrome: a case-control study［J］. Int J Fertil Steril, 2019, 13(3): 203-208.
［16］ Naumova I, Castelo-Branco C, Kasterina I, et al. Quality of life in infertile women with polycystic ovary syndrome: a comparative study［J］. Reprod Sci, 2021, 28(7): 1901-1909.
［17］ Pastoor H, Both S, Laan E, et al. Sexual dysfunction in women with PCOS: a case control study［J］. Hum Reprod, 2023, 38(11): 2230-2238.
［18］ Pastoor H, Timman R, de Klerk C, et al. Sexual function in women with polycystic ovary syndrome: a systematic review and Meta-analysis［J］. Reprod Biomed Online, 2018, 37(6): 750-760.
［19］ Kowalczyk R, Skrzypulec-Plinta V, Nowosielski K, et al. Sexuality in women with polycystic ovary syndrome［J］. Ginekol Pol, 2015, 86(2): 100-106.
［20］ Ercan C M, Coksuer H, Aydogan U, et al. Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome［J］. Int J Impot Res, 2013, 25(4): 127-132.
［21］ Mojahed B S, Ghajarzadeh M, Khammar R, et al. Depression, sexual function and sexual quality of life in women with polycystic ovary syndrome (PCOS) and healthy subjects［J］. J Ovarian Res, 2023, 16(1): 105.
［22］ Stanikova D, Luck T, Pabst A, et al. Associations between anxiety, body mass index, and sex hormones in women［J］. Front Psychiatry, 2019, 10: 479.
［23］ Song S H, Jeon H, Kim S W, et al. The prevalence and risk factors of female sexual dysfunction in young Korean women: an internet-based survey［J］. J Sex Med, 2008, 5(7): 1694-1701.

[1]	Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Ma Jun, Jin Jing. Diagnostic value of multiple androgen indexes measured by LC-MS/MS for polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 602-608.
[2]	Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Yang Yu , Liu Lili, Alfred O. Mueck. The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 623-628.
[3]	Zhang Mingzhen, Ruan Xiangyan, Min Min, Alfred O. Mueck. Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 544-549.
[4]	Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Wang Juan, Cheng Jiaojiao. Investigation on awareness of the benefits from lifestyle intervention in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 555-560.